Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Net sales	$ 4,663	$ 3,856
Cost of products sold	1,453	1,209
Gross profit	3,210	2,648
Operating expenses:
Selling, general and administrative expenses	1,597	1,364
Research and development expenses	443	366
Royalty expense	14	10
Amortization expense	219	214
Contingent consideration net expense (benefit)	5	17
Restructuring net charges (credits)	10	3
Operating expenses	2,288	1,973
Operating income (loss)	921	675
Other income (expense):
Interest expense	(82)	(69)
Other Nonoperating Income (Expense), Net	(34)	2
Income (loss) before income taxes	805	608
Income tax expense (benefit)	133	115
Net income (loss)	672	493
Net income (loss) attributable to noncontrolling interests	(2)	(1)
Net income (loss) attributable to Boston Scientific common stockholders	$ 674	$ 495
Net income (loss) per common share — basic	$ 0.46	$ 0.34
Net income (loss) per common share — diluted	$ 0.45	$ 0.33
Weighted-average shares outstanding
Basic	1,477.2	1,468.4
Diluted	1,493.1	1,481.7